The Europe dermal fillers market is projected to register a substantial CAGR of 10.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029. Market Segmentation: Europe Dermal Fillers Market, By Product Type (Biodegradable Dermal Fillers and Non-Biodegradable Dermal fillers), Material Type (Natural Dermal Fillers and Synthetic Dermal filler), Drug Type ( Branded and Generic), Application (Face Lift, Rhinoplasty, Reconstructive Surgery, Facial Line Correction,Lip, Enhancement, Sagging Skin, Cheek Depression, Skin Smoothing, Dentistry, Aesthetic Restoration, Scar Treatment, Chin Augmentation, Lipoatrophy Treatment, Earlobe Rejuvenation and Others), End User (Dermatology Clinics, Ambulatory Surgical Centers, Hospitals, Academic Research Institutes and Others), Distribution Channel (Direct Tender, Drug Stores, Retail Pharmacy, Online Pharmacy and Others) Country (Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2029 Some of the major factors contributing to the growth of the dermal fillers market are: • Increase in product approval • Increase in geriatric population Market Players: The key market players for the dermal fillers market are listed below: • Allergan (A Subsidiary of Abbvie, Inc.) • Prollenium Medical Technologies • Suneva Medical • Revance Therapeutics, Inc. • FillMed Laboratories • Anika Therapeutics, Inc, • Ipsen Pharma • BIOXIS Pharmaceuticals • Zimmer Aesthetic • Zhejiang Jingjia Medical Technology Co. Ltd. • Medytox • Contura International ltd. • Shanghai Reyoungel Medical Technology Company Limited • Humedix (A subsidiary of HUONS GLOBAL) • Galderma Laboratories, L.P. • Merz North America, Inc. (A Subsidiary of Merz Pharma) • Croma-Pharma GmbH • Sinclair Pharma (A Subsidiary of Huadong Medicine Co., Ltd.) • Teoxane • BioPlus Co., Ltd. • Amalian • Givaudan • Mesoestetic • Sosum Global • DSM • IBSA Nordic ApS

1 INTRODUCTION 24 1.1 OBJECTIVES OF THE STUDY 24 1.2 MARKET DEFINITION 24 1.3 OVERVIEW OF EUROPE DERMAL FILLERS MARKET 24 1.4 LIMITATION 27 1.5 MARKETS COVERED 27 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 PRODUCTS LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 MARKET END USER COVERAGE GRID 45 2.11 VENDOR SHARE ANALYSIS 46 2.12 SECONDARY SOURCES 47 2.13 ASSUMPTIONS 47 3 EXECUTIVE SUMMARY 48 4 PREMIUM INSIGHTS 51 4.1 PORTER’S FIVE FORCES 52 4.2 PESTEL ANALYSIS 53 4.3 EPIDEMIOLOGY PROCEDURES PER COUNTRY 53 5 REGULATIONS OF EUROPE DERMAL FILLERS MARKET 58 6 MARKET OVERVIEW 62 6.1 DRIVERS 64 6.1.1 RISING PREVALENCE OF MINIMALLY INVASIVE PROCEDURES 64 6.1.2 INCREASING GERIATRIC POPULATION 64 6.1.3 TECHNOLOGICAL ADVANCEMENTS IN DERMAL FILLERS 65 6.1.4 STRATEGIC INITIATIVES BY MARKET PLAYERS 65 6.2 RESTRAINTS 66 6.2.1 HIGH COST OF AESTHETIC PROCEDURES 66 6.2.2 ESCALATING PRODUCT RECALL 67 6.2.3 FDA GUIDELINES FOR ADVANCED DERMAL FILLER INJECTORS 67 6.3 OPPORTUNITIES 68 6.3.1 INCREASING HEALTHCARE EXPENDITURE 68 6.3.2 INCREASING FUNDING ACTIVITIES FOR AESTHETIC RESEARCH 68 6.3.3 ADVANCEMENT IN THE NEW DERMAL FILLERS 69 6.3.4 INCREASING COMPENSATION AND ACCIDENTAL CLAIMS FOR DERMAL FILLER 70 6.4 CHALLENGES 71 6.4.1 LACK OF SKILLED PROFESSIONALS 71 6.4.2 AVAILABILITY OF ALTERNATIVES 71 7 EUROPE DERMAL FILLERS MARKET, BY PRODUCT TYPE 72 7.1 OVERVIEW 73 7.2 BIODEGRADABLE DERMAL FILLERS 76 7.2.1 TEMPORARY BIODEGRADABLE 76 7.2.2 SEMI-PERMANENT BIODEGRADABLE 77 7.3 NON-BIODEGRADABLE DERMAL FILLERS 77 8 EUROPE DERMAL FILLERS MARKET, BY MATERIAL TYPE 78 8.1 OVERVIEW 79 8.2 NATURAL DERMAL FILLERS 82 8.2.1 HYALURONIC ACID 82 8.2.1.1 BY TYPE 83 8.2.1.1.1 MONOPHASIC FILLERS 83 8.2.1.2 BY TYPE 83 8.2.1.2.1 MONODENSIFIED 83 8.2.1.2.2 POLYDENSIFIED 83 8.2.1.2.3 BIPHASIC FILLERS 83 8.2.1.3 BY MATERIAL TYPE 84 8.2.1.3.1 SINGLE-PHASE 84 8.2.1.3.2 DUPLEX-PHASE 84 8.2.1.4 BY APPLICATION 85 8.2.1.4.1 FACE LIFT 85 8.2.1.4.2 RHINOPLASTY 85 8.2.1.4.3 RECONSTRUCTIVE SURGERY 85 8.2.1.4.4 FACIAL LINE CORRECTION 86 8.2.1.4.5 LIP ENHANCEMENT 86 8.2.1.4.6 SAGGING SKIN 86 8.2.1.4.7 CHEEK DEPRESSION 86 8.2.1.4.8 SKIN SMOOTHING 86 8.2.1.4.9 DENTISTRY 86 8.2.1.4.10 AESTHETIC RESTORATION 86 8.2.1.4.11 SCAR TREATMENT 86 8.2.1.4.12 CHIN AUGMENTATION 86 8.2.1.4.13 LIPOATROPHY TREATMENT 86 8.2.1.4.14 EARLOBE REJUVENATION 86 8.2.1.4.15 OTHERS 87 8.2.2 FAT 87 8.2.2.1 BY APPLICATION 87 8.2.2.1.1 FACE LIFT 88 8.2.2.1.2 RHINOPLASTY 88 8.2.2.1.3 RECONSTRUCTIVE SURGERY 88 8.2.2.1.4 FACIAL LINE CORRECTION 88 8.2.2.1.5 LIP ENHANCEMENT 88 8.2.2.1.6 SAGGING SKIN 88 8.2.2.1.7 CHEEK DEPRESSION 88 8.2.2.1.8 SKIN SMOOTHING 88 8.2.2.1.9 DENTISTRY 88 8.2.2.1.10 AESTHETIC RESTORATION 88 8.2.2.1.11 SCAR TREATMENT 88 8.2.2.1.12 CHIN AUGMENTATION 89 8.2.2.1.13 LIPOATROPHY TREATMENT 89 8.2.2.1.14 EARLOBE REJUVENATION 89 8.2.2.1.15 OTHERS 89 8.2.3 COLLAGEN 89 8.2.3.1 BY APPLICATION 90 8.2.3.1.1 FACE LIFT 90 8.2.3.1.2 RHINOPLASTY 90 8.2.3.1.3 RECONSTRUCTIVE SURGERY 90 8.2.3.1.4 FACIAL LINE CORRECTION 91 8.2.3.1.5 LIP ENHANCEMENT 91 8.2.3.1.6 SAGGING SKIN 91 8.2.3.1.7 CHEEK DEPRESSION 91 8.2.3.1.8 SKIN SMOOTHING 91 8.2.3.1.9 DENTISTRY 91 8.2.3.1.10 AESTHETIC RESTORATION 91 8.2.3.1.11 SCAR TREATMENT 91 8.2.3.1.12 CHIN AUGMENTATION 91 8.2.3.1.13 LIPOATROPHY TREATMENT 91 8.2.3.1.14 EARLOBE REJUVENATION 91 8.2.3.1.15 OTHERS 92 8.2.4 OTHERS 92 8.3 SYNTHETIC DERMAL FILLERS 92 8.3.1 POLY-L-LACTIC ACID 93 8.3.1.1 BY APPLICATION 93 8.3.1.1.1 FACE LIFT 93 8.3.1.1.2 RHINOPLASTY 93 8.3.1.1.3 RECONSTRUCTIVE SURGERY 94 8.3.1.1.4 FACIAL LINE CORRECTION 94 8.3.1.1.5 LIP ENHANCEMENT 94 8.3.1.1.6 SAGGING SKIN 94 8.3.1.1.7 CHEEK DEPRESSION 94 8.3.1.1.8 SKIN SMOOTHING 94 8.3.1.1.9 DENTISTRY 94 8.3.1.1.10 AESTHETIC RESTORATION 94 8.3.1.1.11 SCAR TREATMENT 94 8.3.1.1.12 CHIN AUGMENTATION 94 8.3.1.1.13 LIPOATROPHY TREATMENT 94 8.3.1.1.14 EARLOBE REJUVENATION 95 8.3.1.1.15 OTHERS 95 8.3.2 CALCIUM HYDROXYLAPATITE 95 8.3.2.1 BY APPLICATION 95 8.3.2.1.1 FACE LIFT 96 8.3.2.1.2 RHINOPLASTY 96 8.3.2.1.3 RECONSTRUCTIVE SURGERY 96 8.3.2.1.4 FACIAL LINE CORRECTION 96 8.3.2.1.5 LIP ENHANCEMENT 96 8.3.2.1.6 SAGGING SKIN 96 8.3.2.1.7 CHEEK DEPRESSION 96 8.3.2.1.8 SKIN SMOOTHING 96 8.3.2.1.9 DENTISTRY 96 8.3.2.1.10 AESTHETIC RESTORATION 96 8.3.2.1.11 SCAR TREATMENT 97 8.3.2.1.12 CHIN AUGMENTATION 97 8.3.2.1.13 LIPOATROPHY TREATMENT 97 8.3.2.1.14 EARLOBE REJUVENATION 97 8.3.2.1.15 OTHERS 97 8.3.3 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA) 97 8.3.3.1 BY APPLICATION 98 8.3.3.1.1 FACE LIFT 98 8.3.3.1.2 RHINOPLASTY 98 8.3.3.1.3 RECONSTRUCTIVE SURGERY 98 8.3.3.1.4 FACIAL LINE CORRECTION 99 8.3.3.1.5 LIP ENHANCEMENT 99 8.3.3.1.6 SAGGING SKIN 99 8.3.3.1.7 CHEEK DEPRESSION 99 8.3.3.1.8 SKIN SMOOTHING 99 8.3.3.1.9 DENTISTRY 99 8.3.3.1.10 AESTHETIC RESTORATION 99 8.3.3.1.11 SCAR TREATMENT 99 8.3.3.1.12 CHIN AUGMENTATION 99 8.3.3.1.13 LIPOATROPHY TREATMENT 99 8.3.3.1.14 EARLOBE REJUVENATION 99 8.3.3.1.15 OTHERS 100 8.3.4 POLYALKYLIMIDE 100 8.3.4.1 BY APPLICATION 100 8.3.4.1.1 FACE LIFT 101 8.3.4.1.2 RHINOPLASTY 101 8.3.4.1.3 RECONSTRUCTIVE SURGERY 101 8.3.4.1.4 FACIAL LINE CORRECTION 101 8.3.4.1.5 LIP ENHANCEMENT 101 8.3.4.1.6 SAGGING SKIN 101 8.3.4.1.7 CHEEK DEPRESSION 101 8.3.4.1.8 SKIN SMOOTHING 101 8.3.4.1.9 DENTISTRY 101 8.3.4.1.10 AESTHETIC RESTORATION 101 8.3.4.1.11 SCAR TREATMENT 101 8.3.4.1.12 CHIN AUGMENTATION 102 8.3.4.1.13 LIPOATROPHY TREATMENT 102 8.3.4.1.14 EARLOBE REJUVENATION 102 8.3.4.1.15 OTHERS 102 8.3.5 OTHERS 102 9 EUROPE DERMAL FILLERS MARKET, BY APPLICATION 103 9.1 OVERVIEW 104 9.2 FACE LIFT 108 9.2.1 DEEP PLANE/SMAS FACE 108 9.2.2 MINI FACE LIFT 108 9.2.3 MID-FACE LIFT 109 9.2.4 JAW LINE 109 9.2.5 CUTANEOUS LIFT 109 9.2.6 TEMPORAL OR BROW LIFT 109 9.2.7 LIQUID FACE LIFT 109 9.2.8 OTHERS 109 9.2.8.1 JUVEDERM 109 9.2.8.2 RESTYLANE 109 9.2.8.3 SCULPTRA 110 9.2.8.4 DYSPORT 110 9.2.8.5 OTHERS 110 9.3 RHINOPLASTY 110 9.3.1 JUVEDERM 111 9.3.1.1 JUVEDERM XC 111 9.3.1.2 JUVEDERM ULTRA XC 111 9.3.1.3 JUVEDERM VOLUMA 111 9.3.1.4 JUVEDERM VOLBELLA 111 9.3.1.5 JUVEDERM VOLLURE XC 111 9.3.2 RESTYLANE 111 9.3.2.1 RESTYLANE SILK 112 9.3.2.2 RESTYLANE LYFT 112 9.3.2.3 RESTYLANE REFYNE 112 9.3.2.4 RESTYLANE DEFYNE 112 9.3.2.5 RESTYLANE-L 112 9.3.3 OTHERS 112 9.4 RECONSTRUCTIVE SURGERY 113 9.4.1 JUVEDERM 113 9.4.2 RESTYLANE 113 9.4.3 OTHERS 113 9.5 FACIAL LINE CORRECTION 114 9.5.1 DYNAMIC WRINKLES 114 9.5.2 STATIC WRINKLES 114 9.5.3 WRINKLE FOLDS 114 9.5.3.1 FOREHEAD LINES 115 9.5.3.2 WORRY LINES 115 9.5.3.3 BUNNIES 115 9.5.3.4 CROW’S FEET 115 9.5.3.5 LAUGH LINES 115 9.5.3.6 LIP LINES 115 9.5.3.7 MARIONETTE LINES 115 9.5.3.8 OTHERS 116 9.5.3.8.1 JUVEDERM 116 9.5.3.8.2 RESTYLANE 116 9.5.3.8.3 RADIESSE 116 9.5.3.8.4 BELOTERO 116 9.5.3.8.5 OTHERS 116 9.6 LIP ENHANCEMENT 117 9.6.1 JUVEDERM 118 9.6.1.1 JUVÉDERM XC 118 9.6.1.2 JUVÉDERM ULTRA XC 118 9.6.1.3 JUVÉDERM VOLUMA 118 9.6.1.4 JUVÉDERM VOLBELLA 118 9.6.1.5 JUVÉDERM VOLLURE XC 118 9.6.2 RESTYLANE 119 9.6.2.1 RESTYLANE SILK 119 9.6.2.2 RESTYLANE LYFT 119 9.6.2.3 RESTYLANE REFYNE 119 9.6.2.4 RESTYLANE DEFYNE 119 9.6.2.5 RESTYLANE-L 119 9.6.3 BELOTERO BALANCE 119 9.6.4 REVANESSE VERSA 119 9.6.5 HYLAFORM 120 9.6.6 PREVELLE SILK 120 9.6.7 OTHERS 120 9.7 SAGGING SKIN 120 9.7.1 JUVEDERM 121 9.7.2 RESTYLANE 121 9.7.3 BELOTERO 121 9.7.4 OTHERS 121 9.8 CHEEK DEPRESSION 121 9.8.1 JUVEDERM VOLUMA 122 9.8.2 RESTYLANE-LYFT 122 9.8.3 SCULPTRA 122 9.8.4 RADIESSE 122 9.8.5 OTHERS 122 9.9 SKIN SMOOTHENING 123 9.9.1 RESTYLANE 123 9.9.2 BELOTERO 123 9.9.3 BELLAFIL 123 9.9.4 OTHERS 124 9.10 DENTISTRY 124 9.10.1 JUVEDERM 124 9.10.2 RESTYLANE 124 9.10.3 RADIESSE 124 9.10.4 OTHERS 125 9.11 AESTHETIC RESTORATION 125 9.11.1 JUVEDERM 126 9.11.1.1 JUVEDERM ULTRA XC 126 9.11.1.2 JUVEDERM VOLLURE XC 126 9.11.1.3 JUVEDERM VOLBELLA XC 126 9.11.2 RESTYLANE 126 9.11.2.1 RESTYLANE-L 127 9.11.2.2 RESTYLANE SILK 127 9.11.2.3 RESTYLANE REFYNE AND DEFYNE 127 9.11.2.4 RESTYLANE LYFT 127 9.12 REVANESSE VERSA 127 9.13 SCULPTRA 127 9.14 RHA 127 9.14.1 RHA 2 128 9.14.2 RHA 3 128 9.14.3 RHA 4 128 9.15 BELLAFIL 128 9.16 BELOTERO BALANCE 128 9.17 OTHERS 128 9.18 LIP PLUM 128 9.18.1 RESTYLANE 129 9.18.2 BELOTERO 129 9.18.3 OTHERS 129 9.19 SCAR TREATMENT 129 9.19.1 JUVEDERM 130 9.19.2 RESTYLANE 130 9.19.3 RADIESSE 130 9.19.4 BELOTERO 130 9.19.5 PERLANE 130 9.19.6 OTHERS 131 9.19.6.1 KELOID SCARS 131 9.19.6.2 CONTRACTURE SCARS 131 9.19.6.3 HYPERTROPHIC SCARS 131 9.19.6.4 ACNE SCARS 131 9.19.6.5 OTHERS 131 9.20 CHIN AUGMENTATION 132 9.20.1 JUVEDERM VOLUMA XC 132 9.20.2 RESTYLANE 132 9.20.3 OTHERS 132 9.21 LIPOATROPHY TREATMENT 133 9.21.1 SCULPTRA 133 9.21.2 OTHERS 133 9.22 EARLOBE REJUVENATION 134 9.22.1 JUVEDERM 134 9.22.2 RESTYLANE 134 9.22.3 SCULPTRA 135 9.22.4 BELOTERO 135 9.22.5 ELLANSE 135 9.22.6 OTHERS 135 9.23 OTHERS 135 10 EUROPE DERMAL FILLERS MARKET, BY DRUG TYPE 136 10.1 OVERVIEW 137 10.2 BRANDED 140 10.2.1 JUVEDERM 141 10.2.1.1 JUVÉDERM XC 141 10.2.1.2 JUVÉDERM ULTRA XC 141 10.2.1.3 JUVÉDERM ULTRA PLUS XC 141 10.2.1.4 JUVÉDERM VOLBELLA 141 10.2.1.5 JUVÉDERM VOLUMA 141 10.2.1.6 JUVÉDERM VOLLURE 141 10.2.2 RESTYLANE 142 10.2.2.1 RESTYLANE-L 142 10.2.2.2 RESTYLANE REFYNE 142 10.2.2.3 RESTYLANE DEFYNE 142 10.2.2.4 RESTYLANE LYFT 142 10.2.2.5 RESTYLANE SILK 142 10.2.2.6 RESTYLANE KYSSE 142 10.2.2.7 RESTYLANE CONTOUR 143 10.2.3 RADIESSE 143 10.2.4 SCULPTRA 143 10.2.5 ELLANSE 143 10.2.5.1 ELLANSE-S 143 10.2.5.2 ELLANSE-M 143 10.2.5.3 ELLANSE-L 143 10.2.5.4 ELLANSE-E 143 10.2.6 BELLAFILL 144 10.2.7 AQUAMID 144 10.2.8 OTHERS 144 10.3 GENERIC 144 11 EUROPE DERMAL FILLERS MARKET, BY END USER 145 11.1 OVERVIEW 146 11.2 DERMATOLOGY CLINICS 149 11.3 HOSPITALS 149 11.4 AMBULATORY SURGICAL CENTERS 150 11.5 ACADEMIC RESEARCH INSTITUTES 150 11.6 OTHERS 151 12 EUROPE DERMAL FILLERS MARKET, BY DISTRIBUTION CHANNEL 152 12.1 OVERVIEW 153 12.2 DIRECT TENDER 156 12.3 DRUG STORES 156 12.4 RETAIL PHARMACY 157 12.5 ONLINE PHARMACY 157 12.6 OTHERS 158 13 EUROPE DERMAL FILLERS MARKET, BY GEOGRAPHY 159 13.1 EUROPE 160 13.1.1 GERMANY 165 13.1.2 ITALY 165 13.1.3 FRANCE 165 13.1.4 U.K. 165 13.1.5 SPAIN 165 13.1.6 RUSSIA 165 13.1.7 NETHERLANDS 165 13.1.8 SWITZERLAND 165 13.1.9 BELGIUM 165 13.1.10 TURKEY 165 13.1.11 REST OF EUROPE 165 14 EUROPE DERMA FILLERS MARKET: COMPANY LANDSCAPE 166 14.1 COMPANY SHARE ANALYSIS: EUROPE 166 15 SWOT ANALYSIS 167 16 COMPANY PROFILE 168 16.1 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 168 16.1.1 COMPANY SNAPSHOT 168 16.1.2 REVENUE ANALYSIS 168 16.1.3 COMPANY SHARE ANALYSIS 169 16.1.4 PRODUCT PORTFOLIO 169 16.1.5 RECENT DEVELOPMENTS 169 16.2 GALDERMA LABORATORIES, L.P 171 16.2.1 COMPANY SNAPSHOT 171 16.2.2 COMPANY SHARE ANALYSIS 171 16.2.3 PRODUCT PORTFOLIO 172 16.2.4 RECENT DEVELOPMENTS 172 16.3 MERZ NORTH AMERICA, INC (A SUBSIDIARY OF MERZ PHARMA) 173 16.3.1 COMPANY SNAPSHOT 173 16.3.2 COMPANY SHARE ANALYSIS 173 16.3.3 PRODUCT PORTFOLIO 174 16.3.4 RECENT DEVELOPMENTS 174 16.4 SINCLAIR PHARMA (A SUBSIDIARY OF HUADONG MEDICINE) 176 16.4.1 COMPANY SNAPSHOT 176 16.4.2 COMPANY SHARE ANALYSIS 176 16.4.3 PRODUCT PORTFOLIO 177 16.4.4 RECENT DEVELOPMENT 177 16.5 REVANCE THERAPEUTICS, INC. 178 16.5.1 COMPANY SNAPSHOT 178 16.5.2 REVENUE ANALYSIS 178 16.5.3 COMPANY SHARE ANALYSIS 179 16.5.4 PRODUCT PORTFOLIO 179 16.5.5 RECENT DEVELOPMENTS 179 16.6 AMALIAN 180 16.6.1 COMPANY SNAPSHOT 180 16.6.2 PRODUCT PORTFOLIO 180 16.6.3 RECENT DEVELOPMENTS 180 16.7 ANIKA THERAPEUTICS, INC. 181 16.7.1 COMPANY SNAPSHOT 181 16.7.2 REVENUE ANALYSIS 181 16.7.3 PRODUCT PORTFOLIO 182 16.7.4 RECENT DEVELOPMENTS 182 16.8 BIOPLUS CO., LTD. 183 16.8.1 COMPANY SNAPSHOT 183 16.8.2 PRODUCT PORTFOLIO 183 16.8.3 RECENT DEVELOPMENTS 184 16.9 BIOXIS PHARMACEUTICALS 185 16.9.1 COMPANY SNAPSHOT 185 16.9.2 PRODUCT PORTFOLIO 185 16.9.3 RECENT DEVELOPMENTS 185 16.10 CONTURA INTERNATIONAL LTD. 186 16.10.1 COMPANY SNAPSHOT 186 16.10.2 PRODUCT PORTFOLIO 186 16.10.3 RECENT DEVELOPMENTS 186 16.11 CROMA-PHARMA GMBH 187 16.11.1 COMPANY SNAPSHOT 187 16.11.2 PRODUCT PORTFOLIO 187 16.11.3 RECENT DEVELOPMENT 187 16.12 DSM 188 16.12.1 COMPANY SNAPSHOT 188 16.12.2 PRODUCT PORTFOLIO 188 16.12.3 RECENT DEVELOPMENT 188 16.13 FILLMED 189 16.13.1 COMPANY SNAPSHOT 189 16.13.2 PRODUCT PORTFOLIO 189 16.13.3 RECENT DEVELOPMENT 189 16.14 GIVAUDAN 190 16.14.1 COMPANY SNAPSHOT 190 16.14.2 RECENT FINANCIALS 190 16.14.3 PRODUCT PORTFOLIO 191 16.14.4 RECENT DEVELOPMENT 191 16.15 HUMEDIX (A SUBSIDIARY OF HUONS EUROPE) 192 16.15.1 COMPANY SNAPSHOT 192 16.15.2 REVENUE ANALYSIS 192 16.15.3 PRODUCT PORTFOLIO 193 16.15.4 RECENT DEVELOPMENTS 193 16.16 IBSA FARMACEUTICI ITALIA SRL (A SUBSIDIARY OF IBSA INSTITUT BIOCHIMIQUE SA) 194 16.16.1 COMPANY SNAPSHOT 194 16.16.2 PRODUCT PORTFOLIO 194 16.16.3 RECENT DEVELOPMENT 194 16.17 IPSEN PHARMA. 195 16.17.1 COMPANY SNAPSHOT 195 16.17.2 REVENUE ANALYSIS 195 16.17.3 PRODUCT PORTFOLIO 196 16.17.4 RECENT DEVELOPMENT 196 16.18 MEDYTROX 197 16.18.1 COMPANY SNAPSHOT 197 16.18.2 PRODUCT PORTFOLIO 197 16.18.3 RECENT DEVELOPMENTS 197 16.19 MESOESTETIC 198 16.19.1 COMPANY SNAPSHOT 198 16.19.2 PRODUCT PORTFOLIO 198 16.19.3 RECENT DEVELOPMENTS 198 16.20 PROLLENIUM MEDICAL TECHNOLOGIES 199 16.20.1 COMPANY SNAPSHOT 199 16.20.2 PRODUCT PORTFOLIO 199 16.20.3 RECENT DEVELOPMENT 199 16.21 SHANGHAI REYOUNGEL MEDICAL TECHNOLOGY COMPANY LIMITED 200 16.21.1 COMPANY SNAPSHOT 200 16.21.2 PRODUCT PORTFOLIO 200 16.21.3 RECENT DEVELOPMENTS 200 16.22 SOSUM EUROPE 201 16.22.1 COMPANY SNAPSHOT 201 16.22.2 PRODUCT PORTFOLIO 201 16.22.3 RECENT DEVELOPMENT 201 16.23 SUNEVA MEDICAL 202 16.23.1 COMPANY SNAPSHOT 202 16.23.2 PRODUCT PORTFOLIO 202 16.23.3 RECENT DEVELOPMENT 202 16.24 TEOXANE SA 203 16.24.1 COMPANY SNAPSHOT 203 16.24.2 PRODUCT PORTFOLIO 203 16.24.3 RECENT DEVELOPMENTS 203 16.25 ZHEJIANG JINGJIA MEDICAL TECHNOLOGY CO., LTD 205 16.25.1 COMPANY SNAPSHOT 205 16.25.2 PRODUCT PORTFOLIO 205 16.25.3 RECENT DEVELOPMENT 205 16.26 ZIMMER AESTHETICS 206 16.26.1 COMPANY SNAPSHOT 206 16.26.2 PRODUCT PORTFOLIO 206 16.26.3 RECENT DEVELOPMENTS 206 17 QUESTIONNAIRE 207 18 RELATED REPORTS 211